Marker Therapeutics (MRKR) EPS (Weighted Average and Diluted) (2011 - 2026)
Marker Therapeutics (MRKR) reported EPS (Weighted Average and Diluted) of -$0.16 for Q1 2026, up 60.0% year-over-year from -$0.1 in Q1 2025, and down 300.0% quarter-over-quarter from -$0.04 in Q4 2025.
Marker Therapeutics (MRKR) EPS (Weighted Average and Diluted) (2011 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 13 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.16 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.16, up 60.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.61 (up 54.14% YoY), and the FY2025 annual result was -$0.79, up 33.61% from the prior year.
- EPS (Weighted Average and Diluted) retreated to -$0.16 in Q1 2026 per MRKR's latest filing, from -$0.04 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.29 in Q2 2023 and troughed at -$1.57 in Q4 2022.
- A 5-year average of -$0.49 and a median of -$0.34 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) plunged 753.85% in 2022, then jumped 126.13% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.57 in 2022, then jumped by 38.22% to -$0.97 in 2023, then soared by 56.7% to -$0.42 in 2024, then surged by 90.48% to -$0.04 in 2025, then slumped by 300.0% to -$0.16 in 2026.
- Business Quant data shows MRKR's EPS (Weighted Average and Diluted) at -$0.16 in Q1 2026, -$0.04 in Q4 2025, and -$0.12 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | -0.16 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.16 |
| Dec 31, 2025 | -0.04 |
| Sep 30, 2025 | -0.12 |
| Jun 30, 2025 | -0.29 |
| Mar 31, 2025 | -0.40 |
| Dec 31, 2024 | -0.42 |
| Sep 30, 2024 | -0.26 |
| Jun 30, 2024 | -0.25 |
| Mar 31, 2024 | -0.27 |
| Dec 31, 2023 | -0.97 |
| Sep 30, 2023 | -0.34 |
| Jun 30, 2023 | 0.29 |
| Mar 31, 2023 | -0.48 |
| Dec 31, 2022 | -1.57 |
| Sep 30, 2022 | -0.83 |
| Jun 30, 2022 | -1.11 |
| Mar 31, 2022 | -1.19 |
| Dec 31, 2021 | -5.04 |
| Sep 30, 2021 | -0.15 |
| Jun 30, 2021 | -0.13 |